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CD6isa105–130kDasurfaceglycoproteinexpressedonthemajorityofTcellsandasubsetofBcells.Thehumancd6 genemapsto
chromosome11,andtheexpressionofitsproteinproductistightlyregulated.CD6mediatescellularadhesionmigrationacrossthe
endothelial and epithelial cells. In addition, it participates in the antigen presentation by B cells and the subsequent proliferation
of T cells. CD6 may bind in trans to surface glycoproteins (such as ALCAM and 3A11), or to microbial lipopolysaccharides, and
may bind in cis to endogenous ligands (such as CD3 and CD5), and thereby deliver a costimulatory signal. Transinteractions are
reinforced during autoimmune diseases (e.g., rheumatoid arthritis (RA), Sj¨ ogren’s syndrome, and multiple sclerosis) and some
cancers. Based on experimental data and on clinical results in RA and psoriasis, we believe that the recent humanized anti-CD6-
speciﬁc mAb T1h may act as a regulator of the immunological response in addition to its function as an anti-T- and -B cell agent.
1.Introduction
The past few years have witnessed increasing interest in
the possibility that B lymphocytes are cast with a leading
role in the play of autoimmunity. Treatment with B cell-
depleting agents has thus become the logics. Among these
is the anti-CD6 antibodies (Abs), because CD6 is harboured,
not only by all T cells, but also by some B cells. The earliest
successes of anti-CD6 Abs in autoimmune diseases [1–3]
were obtained in the treatment of rheumatoid arthritis (RA),
psoriasis, and multiple sclerosis (MS) (Table 1). In spite of
such promising results, the investigators had to give up [4, 5]
due to the murine origin of their monoclonal Abs (mAbs).
There was thus a need for humanized anti-CD6 mAb.
This task was accomplished by mutagenesis in 2003 using
the murine anti-CD6 single scavenger receptor cystein-rich
(SRCR) domain 1, ior T1 [6, 7]. The resulting humanized
anti-CD6 mAb was termed T1h, and evaluated in RA and
psoriasis. The preliminary results in active RA [8] revealed
that the combination of T1h, with methotrexate resulted in a
long-term remission with a signiﬁcative reduction of swollen
and tender joints. The question, therefore, arises as to how
the anti-CD6 T1h mAb work? First, one might argue that
anti-CD6 Ab should target the T cells, as well. Were that to
be the case, a T-cell depletion should be elicited such was not
the case. Second, it may block interactions between CD6 and
the activated leukocyte cell adhesion molecule (ALCAM).
However, in vivo experiments and in vitro competition assays
have cast doubt on this possibility. By self-deﬁnition, it is
important to deﬁne the rationale for using anti-CD6 mAb in
autoimmune diseases. The present review summarizes our
knowledge regarding CD6, its functions, and the diﬀerent
anti-CD6 mAbs that have been developed and tested.
2. CD6 from the Gene to the Protein
2.1. cd6 Gene. The gene for cd6,aT - c e l ld i ﬀerentiation
antigen (Ag) maps to chromosome 11 at position 11q13.1,
spans more than 25-kb adjacently, and adjoins the cd5 gene
within 200-kb telomeric to cd20 in human [9]. In mice
and chicken, the cd6 gene is present on chromosome 19
and 5, respectively, [10, 11]. Phylogenetic analysis supports2 Arthritis
Table 1: Anti-CD6 and clinical studies.
Clone Diseases Eﬀect Author
Ior T1 Tc e l ll y m p h o m a ,
Psoriasis Clinical improvement [1]
Ior T1-
99Tcm Rheumatoid arthritis Clinical improvement [2]
T12 Multiple sclerosis T cell depletion [3]
T12 BM transplantation in
SCID patient
Prevent acute GvH
disease [4]
T12 Allogeneic BM
transplantation T cell elimination [5]
GvH disease: graft-versus-host disease; BM: bone marrow, IV: intravenous;
SCID: severe combined immunodeﬁciency.
the concept that cd6 and cd5 have emerged from duplication
of a common ancestor, probably before the separation of
mammalian/birds and amphibian 200–300 million years ago
(Figure 1). Interestingly, in humans, but not in mice, an
endogenousretrovirustypeEisinsertedbetweencd6 andcd5
genes,andservesasanalternativegenepromoterforcd5.The
inﬂuence on cd6 is unknown [12, 13].
A minimal cd6 promoter has been recently described at
positions −506/−146 from the start codon ATG (+1) [14].
Mutational analysis of the promoter and characterization of
related transcription factors (TFs) have identiﬁed Ets-1 and
RUNX1/3 as cd6 regulators. Likewise, cd5 gene is positively
regulated by Ets-1 and NFAT, and negatively regulated by
E47 [15–17]. The inhibitory eﬀect of E47 on the expression
of CD6 has never been described, even though the cd6
promoter contains an E-box-binding domain at position
−273.Inaddition,cd6 promoterisregulatedattheepigenetic
level through methylation of its 15 CpG motifs between
positions −300/+1. As observed by treating cloned human T
cells with the DNA methylation inhibitor 5-azacytidine [18].
RNase protection assay and 5 RACE RT-PCR show
multiple transcriptional start sites in accordance with the
absence of TATA box in the 5  ﬂanking region of cd6[ 14]. In
humans,exon1containsthestartcodonandexon13contain
the stop codon. In between, a nucleotide-long-related open
reading frame corresponds to a 668-amino acid (aa) protein.
Exons 1 and 2 encode the 24-aa signal sequence, exons 3
through 5 encode each a 101/117-aa SRCR domain, exon
6 encodes a 22-aa spacer that separates the SRCR-D3 from
the exon 7-encoded 26-aa transmembrane domain, while
exons 8 through 13 encode the cytoplasmic domain of CD6
(Figure 2). Analysis of single-nucleotide polymorphisms
(SNPs) in the cd6 locus has unveiled association between MS
and the SNP rs17824933 in exon 1 [19, 20]. Besides this well-
known SNP which is associated with CD6 lower expression
[21], another 8 nonsynonymous SNPs characterize the
coding region but their eﬀects are unknown.
2.2. CD6 Transcripts. Hematopoietic precursors thymocytes,
mature T and NK cells, a subset of normal B lymphocytes
andmostofthosefromlymphocyticchronicleukemia(CLL)
transcribe mRNAs for CD6. In B cells, CD6 expression
predominates in mature B cells (usually in association with
CD5) which make IgM, but do not isotype switch [22]. CD6
mRNAisalsodetectedinvariousbrainregions,mostnotably
in basal ganglia and cortex cerebellum [23, 24].
Northern blot detects a 3-kb band corresponding to
CD6 mRNA in T lymphocytes and brain cells. Its intensity
augments after exposure to phorbol myristic acetate (PMA),
a protein kinase C activator (PKC), or incubation with
phytohaemagglutinin (PHA). Controversy persists over the
inﬂuence of the B-cell Ag receptor (BCR) engagement on
CD6 expression. Some authors, but not all, observed an
induction of CD6 upon anti-IgM or superantigen Staphylo-
coccus aureus Cowan I stimulation [22, 25].
Among the mRNAs for CD6, several alternative splices
have been identiﬁed by RT-PCR, and conﬁrmed by sequenc-
ing (Figure 2): one lacking exon 5 (CD6ΔD3) in T cells, and
at least four isoforms lacking exon(s) for the cytoplasmic
domain of CD6: Δ8, Δ8-9, Δ8/Δ12 or Δ9/Δ12 in CLL [26].
Anexon9-lackingsplicoformhasalsobeendescribedinmice
[27, 28]. CD6ΔD3 expression is upregulated throughout the
maturation of thymocytes, and following stimulation with
PHA [29]. However, the full-length CD6-encoding cDNA
predominate in resting and activated cells.
2.3.CD6Protein. Ofthe105kDa-molecularweight(MW)of
glycoprotein, 35kDa are accounted for by polysaccharides.
This heavy glycosylation is rendered possible by eight
putative sites for N-glycosylation and two putative sites for
O-glycosylation in the extracellular part of the molecule. In
addition, when lymphocytes are activated by PMA or by
fetal calf serum, CD6 serine, threonine, and tyrosine (Y)
residues are hyperphosphorylated and the MW of the related
band increased from 105 to 130kDa [30]. Comparison of the
CD6 SRCR domains between human and mouse shows 54%
aa identity for SRCR-D1, 84% for SRCR-D2, and 81% for
SRCR-D3[7],and69%forthetransmembranedomain [28].
The 244-aa cytoplasmic tail of CD6 harbors nine thre-
onine and 32 serine residues. Two proteins, SLP-76 and
synthenin-1, may be physically associated with Y662 of
human CD6 [31, 32]. Of note, SLP-76 that activate PKC
and MAPK pathways requires Y662 phosphorylation to
bind CD6 [31, 33]. Synthenin-1 is important in protein
traﬃcking, cell adhesion, and activation of Sox4 and eIF5A
TFs. In rat, CD6 associates with diﬀerent protein tyrosine
kinases, including Lck, Fyn, Zap-70, and Itk [34].
In T and B cells, interactions with kinases are reinforced
when aa are Y phosphorylated upon PMA or, anti-CD3
stimulation, with, but also without, CD2 or CD4 cross-
linking [35, 36]. Ligation of CD6 with anti-CD6 mAb on
both normal and leukemic human T cells triggers oﬀ the
activation of the MAPK cascade with phosphorylation of
Erk1/2, p38 and JNK [37]. However, cross-linking the anti-
CD6 mAb is required to launch the MAPK pathways.
3.Biological Functions
3.1. CD6-Positive and CD6-Negative Cells. There are no
CD6 knockout or CD6-knockin mice, yet CD6-positive cells
and CD6-negative cells were compared in T and B cells.Arthritis 3
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Figure 1: CD6 and CD5 genes map to contiguous regions in mammalian and birds and are supposed to have arisen for implication of a
common ancestral gene. CD6 is orthologue to the amphibian protein CD5/CD6 and the ﬁsh protein 14d8. Data has been taken from the
genome database (http://www.ensembl.org/) and from previously published results [11, 13]. Black boxes represent the exons encoding the
extracellularSRCRdomains.Firstandlastexonsaredepictedwhenknown.Legend:HERVhumanendogenousretrovirus;CA:microsatellite
repeat, My: million year.
In T cells, CD6-positive lymphocytes proliferate more than
CD6-negative lymphocytes in the presence of stimulation
by allo-Ag presenting cells (APCs) [38]. T- and B-cell
proliferation in response to mitogens is similar in CD6-
positive cells and in CD6-negative cells [22, 38]. The latter
B cells, in the presence of T cells and PMA, produce high
amount of IgM and IgG, whereas CD6-positive B cells
produce little IgM, and do not make IgG [22].
3.2. Transligation
3.2.1. Main CD6 Ligand. ALCAM belongs to the immuno-
globulin (Ig) cell adhesion molecule superfamily. It is
expressed on bone marrow (BM) stromal cells, thymic
epithelial cells, activated T and B cells, monocytes, dendritic
cells, synovial ﬁbroblasts, keratinocytes, and mesangial stem
cells. ALCAM was identiﬁed as a ligand of CD6 [39, 40].
ALCAM expression is tightly regulated, and indeed mitogen-
activated peripheral blood mononuclear cells (PBMCs)
express ALCAM for 24 to 48h, but not thereafter [41].
The extracellular region of ALCAM consists of ﬁve
extracellular Ig domains (D1–D5). The two NH2-terminal
domains are related to variable (V)-type and the three
proximal domains to constant(C)-type Ig domains. The N-
terminal domain of ALCAM interacts with the conserved
SRCR-D3 of CD6, while the C-proximal domains oligomer-
ize ALCAM. The CD6 binding domain for ALCAM is
highly conserved, explaining the cross-species CD6/ALCAM
interaction between humans, mice, and chickens. This is
also the reason why it is so diﬃcult to mount an Ab
response against the CD6 binding site [41]. Like most other
leukocyte membrane interactions, the heterotypic ALCAM-
CD6 interaction is of low aﬃnity, albeit 10- to 100-fold
higher than the homotypic ALCAM-ALCAM interaction
[42]. Binding studies with CD6 fusion proteins has revealed
that CD6-SRCR-D2 (exon 4) and CD6 spacer domain (exon
6) are important to stabilize the interaction between CD6-
SRCR-D3 and ALCAM [43]. Mutagenesis analysis has shown
that three residues in the C-terminal region of CD6-SRCR-
D3andnineresiduesintheALCAM-D1domainareinvolved
in the binding/interaction CD6/ALCAM [44].
The binding of CD6 to ALCAM is dominant for CD34+
hematopoietic progenitor binding to BM stromal cells [45],
thymocyte binding to thymic epithelial cells [39, 40], and
T-cell-dependent proliferation [46]. In pathological settings,
supplemental functions have been ascribed to the complex
CD6/ALCAM. First, CD4+-T-cell transmigration into the
centralnervoussystemisrelatedtoCD6/ALCAMinteraction4 Arthritis
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Figure 2: Human CD6 transcripts. (a) Diagram of the human CD6 gene exons which are depicted as boxes numbered from 1 to 13. (b)
Representation of the diﬀerent CD6 isoforms. (c) Scheme of the CD6 protein. The localization of the diﬀerent binding domains is indicated.
attheborderbetweenbloodandbrain[47].Second,ALCAM
overexpression entrances the lymphocyte recruitment to
inﬂammatory sites, including RA synovium, SS exocrine
glands, MS brain, and microenvironment of selected cancers
[47–50].
3.2.2. Accessory Ligands for CD6. The list of CD6 ligands is
extremely long, based on the observation that CD6 fusion
protein immunoprecipitate from a human epithelial cell live
not only with ALCAM, but also with a 90-kDa and a 45-kDa
proteins [51].Anotherclue toadditional ligand(s)forCD6 is
that the binding of T cells to epithelial cells cannot be totally
blocked by anti-CD166 Ab and by anti-CD6 SRCR-D3 Ab
[52].
Following activation with IFN-γ a 130-kDa protein
designated3A11arisesonsynovialﬁbroblasts,thymicﬁbrob-
last, and keratinocytes [52–54]. The interaction could be
abrogated by a CD6 fusion protein or an anti-CD6 SRCR-
D1 Ab suggesting that CD6 domain SRCR-D1 recognizes
alternative ligands.
3.2.3. Pathogen Recognition. The Lozano’s group has recently
reported on the binding of CD6 and CD5 to pathogen-
associated molecular patterns [55, 56]. Catching of pathogen
by CD6 is dose dependent, saturable, facilitated by calcium,
and achieved by the three SRCR domains. Microbes induce
signaling with MAPK/Erk activation and cytokine release.
This Toll-like receptor-independent process requires the
integrity of the cytoplasmic domain as demonstrated with
CD5. Interestingly, soluble CD6 and CD5 have been detected
in normal human sera, and their levels found to be increased
in autoimmune diseases, thus suggesting a feedback loop to
reduce direct lymphocyte activation by pathogens [57, 58].
3.3. Cis Ligation
3.3.1. CD6-CD3 Interactions and Immunological Synapse.
T h ej u n c t i o nb e t w e e naTl y m p h o c y t ea n da nA P Ci s
designated as immunological synapse (IS) and assigned to
an active mechanism. First, T-cell Ag receptor (TCR) ligands
and costimulatory molecules are engaged in an external ring
of the nascent IS, translocated into the central cluster, and
ﬁxed in the heart of the IS. Finally, the IS consists of the
central supramolecular activation cluster (cSMAC) enriched
in TCR/CD3 complexes, CD4/CD8/CD2/CD5 costimulatory
molecules, and kinases (PKC, Lck and Fyn), and surrounded
by a supramolecular activation clusters (pSMAC) including
LFA-1 and talin.
The fact that CD6 exists both in pSMAC and in cSMAC
suggests the possibility of two functions, each being related
to its location [29, 59, 60]. At the pSMAC, CD6 binds to
ALCAM. This is stable, long lasting and involved in the
contact initiation between T cells and APCs. Then blocking
CD6-ALCAM interaction reduces signiﬁcantly T-cell/APC
contact and impairs the T-cell proliferation. This could be
achieved with anti-CD6-SRCR-D3 Ab or ALCAM-blocking
Ab. In addition, when the cells express an alternative isoform
of CD6, CD6ΔD3, devoid of ALCAM binding domain, the
contact of lymphocytes with APC is lost [29]. At the cSMAC,
CD6 is physically associated with the TCR/CD3 complex,Arthritis 5
and, as such, participates in the proliferation of T cells. Since
T1h related anti-CD6-SRCR-D1 Ab are able to inhibit T-cell
proliferationwithoutaﬀectingT-cell/APCcontactitcouldbe
postulatedthatthisinteractioninvolvedtheSRCR-D1partof
CD6.
3.3.2. CD6 and CD5 Association. Confocal microscopy,
coupledwiththeFRETtechnology [61],establishesthat12%
of the CD6 molecules are associated with CD5 molecules in
resting T cells. Upon activation, this association is reinforced
and the CD6-CD5 complexes migrate to the IS where
they colocalize with TCR/CD3 within the cSMAC. Of note,
complexes of cross-linked CD5 and CD6 are internalized,
and, by doing so, conﬁrm their physical link.
Interactions between CD6 and CD5 proceed through
their extracellular domains given that, despite truncation
of its intracellular tail, CD5 keeps its ability to bind CD6.
Which CD6 extracellular domain is involved is currently
unknown. The CD5-CD6 interaction is not unique, since
CD5 SRCR-D2 interact with the BCR [62], CD5 SRCR-
D3 interferes with itself [63] and interacts with CD2 [64].
Interestingly, when CD6 and CD5 are physically associated,
CD6 is phosphorylated on its Y629 and CD5 on its Y429,
suggesting that their association contributes to TCR- or
BCR-independent activation. This was demonstrated in rat
T cells by immunoprecipitation where CD5 was associated
with hyperphosphorylated 130-kDa CD6, and CD6 with
hyperphosphorylated CD5 [65].
Over the thymic maturation, the expression CD6, that of
CD5 (and thereby their interactions) are tightly regulated,
and contributes to the thymocyte selection. Immature
double-negative CD4−CD8− thymocytes express CD6 and
low levels of CD5, at immature double-positive CD4+CD8+
stage CD6 expression is stable and CD5 is increased, ﬁnally
at single-positive CD4+ or CD8+ stages both molecules
are highly expressed [66, 67]. When compared to single-
positive thymocytes, cell surface expression on resting
peripheral blood T cells is lower for CD6 and similar for
CD5.
Within the B lymphocytes, the CD6-expressing cells
overlap, but not entirely, with the CD5-expressing cells [68].
CD5-expressing B cell, designated B1 cells, as opposed to
conventional CD5-nonexpressing B2 cells, produce polyspe-
ciﬁcAbsand,therefore,constitutethemainsourceofnatural
Abs. In fact, the CD6 molecule acts as a positive regulator of
the BCR while CD5 is a negative regulator.
4. Anti-CD6 Immunotherapy
4.1. Anti-CD6 Monoclonal Abs. Diﬀerent anti-CD6 mAbs
have been raised, mainly against the ﬁrst and third SRCR
domains of CD6. Four main epitopes are described in the
SRCR-D1 [69]. Brieﬂy, anti-CD6-SRCR-D1 mAbs hinder
autoreactive and nonautoreactive T-cell proliferation while
anti-CD6-SRCR-D3 mAb prevents the adhesion and Ag-
dependent activation of lymphocytes via its interaction with
ALCAM (Table 2 and Figure 3).
LigationoftheCD6cellsurfacemoleculebycross-linking
an anti-SRCR-D1 mAb mimics the CD6-CD166 interaction
Table 2: Anti-CD6 SRCR-D1 mAbs and functional eﬀects.
Clone Functional response Cross-
link Author
BLTP6a, UMCD6 and
MT502
Block T-cell Ag
dependant activation No [18]
161.8 Induces Erk1/2
activation Yes [37]
IorT1, 2H1, T12, 6D3,
Dako-CD6
Enhance anti-CD3,
anti-CD28 and PMA T
cell proliferation
Yes [70, 71]
Ior T1 Protects B-CLL from
anti-IgM apoptosis Yes [25]
UMCD6
Blocks
T-cell/keratinocyte
interaction
No [18]
and delivers a direct signal by activating MAPK [37, 55].
T-cell proliferation could be achieved or ampliﬁed when
ligation of the CD6 molecule is associated with a second
signal mediated by the ligation of CD3, CD28, or with PMA
[69]. This proliferation is IL-2 dependent.
In B cells, CD6 ligation was not found to induce the
proliferative response of CLL but to protect from anti-IgM-
mediated apoptosis through bcl-2 induction [25]. CLL B-
cell spontaneous apoptosis is not aﬀected by CD6 cross-
linking.
4.2. Anti-CD6 and Clinical Studies. The murine IgM anti-
T12/CD6 mAb has been used experimentally in vivo as an
anti-T-cell agent in MS, leukaemia, in acute graft-versus-
host GvH disease, and in acute renal transplant rejection [3,
4, 72]. However, circulating CD6-positive T cells disappear
completely the ﬁrst week, the appearance of blocking human
anti-mouse IgM in the serum by 78% of the patients, seven
days after infusion, together with allergic reactions limits the
eﬃciency of the mAb. In addition, the anti-T12/CD6 mAb
associated with rabbit complement was also used ex vivo
for removing T cells from the donor BM, as an attempt to
reducetheincidenceofacuteandchronicGvHdisease.These
allogeneic CD6-depleted BM transplantations have been
used successfully in patients with hematologic malignancies
a n ds e v e r ec o m b i n e di m m u n o d e ﬁ c i e n c y[ 73, 74]. After BM
transplantation, NK cells are reconstituted early, and T
cells are detected after four to eight weeks including T-cell
functional abnormalities and a signiﬁcant fraction of CD6-
nonexpressing T cells [75]. A decade ago, transplantation
of anti-T12/CD6 T-cell-depleted BM was supplanted by the
selection of stem cells CD34+.
CD6 mAb ior T1 (IgG2a,k) was raised in BALB/c
mice immunized with PBMCs from a patient with Sezary’s
syndrome [6, 7]. Ior T1 mAb, another anti-CD6 SRCR-
D1 mAb, has been used with success in cutaneous T-cell
lymphoma and in a patient with psoriasis [1]. A technetium-
99m-labeled ior T1 mAb was tested in a phase II clinical trial
in RA demonstrating a link between the concentration used
and the clinical improvement [2].6 Arthritis
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Figure 3: CD6 functions according to the CD6 scavenger receptor
cystein-rich (SRCR) domain involved.
4.3. Humanized Anti-CD6 Monoclonal Ab. To reduce its
immunogenicity,iorT1mAbhasbeengeneticallyengineered
to progressively replace murine content with the human
counterparts. In the ﬁrst step, a chimeric human-mouse IgG
was generated by exchanging corresponding heavy chain C
domains between the human IgG1 and the murine IgG2a.
In the second step, the two homologous mouse and human
V region sequences were compared and Ag sequences of
T cells were analyzed. In the third step, 11 aa present in
the V region were subjected to point mutations to make
them human and/or to modify amphiphatic motifs [6].
The resulting recombinant Ab (T1h) retained its Ag-binding
aﬃnity and was less immunogenic than the murine original
[6, 7]. Humanized anti-CD6 T1h recognizes a conforma-
tional epitope independent of the CD6 N-glycosylation of
SRCR-D1. As suspected, it does not block CD6-ALCAM
interactions suggesting that T1h could not inhibit ALCAM-
related T-cell activation and prevent T-cell migration.
5. Conclusions
CD6 SRCR-D1 contributes to lymphocyte proliferation,
adhesion and survival process. Indeed, the humanized anti-
CD6 SRCR-D1 clone T1h which does not interfere with the
CD6-ALCAM interactions may have therapeutic implica-
tions in oncology, transplantation, and autoimmunity. The
recent data obtained with soluble recombinant CD6 in an
experimental model of septic stock support this model.
Acknowledgments
This work was supported by grants from the Ligue Contre
le Cancer (comit´ es 22, 29, and 56), the Conseil R´ egional
de Bretagne, the Conseil G´ en´ eral du Finist` ere, and the
FrenchMinistryforEducationandResearch.Theauthorsare
grateful to Simone Forest for her secretarial assistance.
References
[ 1 ]E .M o n t e r o ,L .F a l c o n ,Y .M o r e r a ,J .D e l g a d o ,J .F .A m a d o r ,
and R. Perez, “CD6 molecule may be important in the
pathological mechanisms of lymphocytes adhesion to human
skin in psoriasis and ior t1 MAb a possible new approach to
treat this disease,” Autoimmunity, vol. 29, pp. 155–156, 1999.
[2] E. Montero, G. Reyes, M. Guibert et al., “Immunodiagnosis
and therapeutic immunosuppression in rheumatoid arthri-
tis with ior t1 (anti-CD6) monoclonal antibody,” Arthritis
Research & Therapy, vol. 4, article 38, 2002.
[ 3 ]D .A .H a ﬂ e r ,R .J .F a l l i s ,a n dD .M .D a w s o n ,“ I m m u n o l o g i c
responses of progressive multiple sclerosis patients treated
with an anti-T-cell monoclonal antibody, anti-T12,” Neurol-
ogy, vol. 36, no. 6, pp. 777–784, 1986.
[4] E. L. Reinherz, R. Geha, J. M. Rappeport et al., “Reconsti-
tution after transplantation with Tlymphocyte-depleted HLA
haplotype-mismatched bone marrow for severe combined
immunodeﬁciency,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 79, pp. 6047–6051,
1982.
[5] D. Resnick, A. Pearson, and M. Krieger, “The SRCR super-
family: a family reminiscent of the Ig superfamily,” Trends in
Biochemical Sciences, vol. 19, no. 1, pp. 5–8, 1994.
[6] L. Roque-Navarro, C. Mateo, J. Lombardero et al., “Human-
ization of predicted T-cell epitopes reduces the immunogenic-
ity of chimeric antibodies: new evidence supporting a simple
method,” Hybridoma and Hybridomics, vol. 22, no. 4, pp. 245–
257, 2003.
[7] R. Alonso, V. Huerta, J. De Leon et al., “Towards the deﬁnition
ofachimpanzeeandhumanconservedCD6domain1epitope
recognized by T1 monoclonal antibody,” Hybridoma, vol. 27,
no. 4, pp. 291–301, 2008.
[8] E. Montero, R. Casaco, Z. Muzzora, R. Alonso-Ramirez, and
R. Parey, “Pharmaceutical composition, comprising an anti-
CD6 mAb used in the diagnosis and treatment of rheumatoid
arthritis,” EP2119452, 2009.
[ 9 ]O .L e c o m t e ,J .B .B o c k ,B .W .B i r r e n ,D .V o l l r a t h ,a n dJ .R .
Parnes,“MolecularlinkageofthemouseCD5andCD6genes,”
Immunogenetics, vol. 44, no. 5, pp. 385–390, 1996.
[ 1 0 ]O .P a d i l l a ,J .C a l v o ,J .M .V i l ` a et al., “Genomic organization
of the human CD5 gene,” Immunogenetics, vol. 51, no. 12, pp.
993–1001, 2000.Arthritis 7
[11] R. Koskinen, J. Salomonsen, M. Goodchild, N. Bumstead, Y.
Boyd,andO.Vainio,“Structureandchromosomallocalization
of chicken CD5,” Scandinavian Journal of Immunology, vol. 54,
no. 1-2, pp. 141–145, 2001.
[12] Y. Renaudineau, S. Hillion, A. Saraux, R. A. Mageed, and P.
Youinou, “An alternative exon 1 of the CD5 gene regulates
CD5expressioninhumanBlymphocytes,” Blood,vol.106,no.
8, pp. 2781–2789, 2005.
[13] Y. Renaudineau, S. Vallet, C. Le Dantec, S. Hillion, A.
Saraux, and P. Youinou, “Characterization of the human
CD5 endogenous retrovirus-E in B lymphocytes,” Genes and
Immunity, vol. 6, no. 8, pp. 663–671, 2005.
[14] M. Arman, N. Aguilera-Montilla, V. Mas et al., “The human
CD6 gene is transcriptionally regulated by RUNX and Ets
transcription factors in T cells,” Molecular Immunology, vol.
46, no. 11-12, pp. 2226–2235, 2009.
[15] M. Arman, J. Calvo, M. E. Trojanowska et al., “Transcriptional
regulation of human CD5: important role of Ets transcription
factors in CD5 expression in T cells,” Journal of Immunology,
vol. 172, no. 12, pp. 7519–7529, 2004.
[16] R. Berland and H. H. Wortis, “An NFAT-dependent enhancer
is necessary for anti-IgM-mediated induction of murine CD5
expression in primary splenic B cells,” Journal of Immunology,
vol. 161, no. 1, pp. 277–285, 1998.
[17] Y. Yang, C. H. Contag, D. Felsher et al., “The E47 transcription
factor negatively regulates CD5 expression during thymocyte
development,” Proceedings of the National Academy of Sciences
oftheUnitedStatesofAmerica,vol. 101, no.11, pp. 3898–3902,
2004.
[18] N. G. Singer, B. C. Richardson, D. Powers et al., “Role of
the CD6 glycoprolein in antigen-speciﬁc and autoreactive
responses of cloned human T lymphocytes,” Immunology, vol.
88, no. 4, pp. 537–543, 1996.
[19] P. L. De Jager, X. Jia, J. Wang et al., “Meta-analysis of genome
scans and replication identify CD6, IRF8 and TNFRSF1A as
new multiplesclerosis susceptibility loci,” Nature Genetics,vol.
41, no. 7, pp. 776–782, 2009.
[20] B. Swaminathan, F. Matesanz, M. L. Cavanillas et al., “Valida-
tionoftheCD6andTNFRSF1Alociasriskfactorsformultiple
sclerosis in Spain,” Journal of Neuroimmunology, vol. 223, no.
1-2, pp. 100–103, 2010.
[21] G. A. Heap, J. H. M. Yang, K. Downes et al., “Genome-wide
analysisofallelicexpressionimbalanceinhumanprimarycells
by high-throughput transcriptome resequencing,” Human
Molecular Genetics, vol. 19, no. 1, pp. 122–134, 2009.
[22] N. Endres, G. Riethmueller, and E. P. Rieber, “Functional
characterization of a novel B-cell subset deﬁned by the CD6
antigen,” in Leukocyte Typing IV,W .K n a p p ,B .D o e r k e n ,W .
R. Gilks et al., Eds., pp. 340–351, Oxford University Press,
Oxford, UK, 1989.
[23] B. Mayer, I. Funke, B. Seed, G. Riethmuller, and E. Weiss,
“Expression of the CD6 T lymphocyte diﬀerentiation antigen
innormalhumanbrain,”JournalofNeuroimmunology,vol.29,
no. 1–3, pp. 193–202, 1990.
[24] A. Konno, J. S. Ahn, H. Kitamura et al., “Tissue distribution of
CD6 and CD6 ligand in cattle: expression of the CD6 ligand
(CD166) in the autonomic nervous system of cattle and the
human,” Journal of Leukocyte Biology, vol. 69, no. 6, pp. 944–
950, 2001.
[25] L. M. Osorio, A. De Santiago, M. Aguilar-Santelises, H.
Mellstedt, and M. Jondal, “CD6 ligation modulates the Bcl-
2/Bax ratio and protects chronic lymphocytic leukemia B cells
from apoptosis induced by anti-IgM,” Blood, vol. 89, no. 8, pp.
2833–2841, 1997.
[26] M. A. Bowen, G. S. Whitney, M. Neubauer et al., “Structure
and chromosomal location of the human CD6 gene: detection
ofﬁvehumanCD6isoforms,”JournalofImmunology,vol.158,
no. 3, pp. 1149–1156, 1997.
[27] G. Whitney, M. Bowen, M. Neubauer, and A.Aruﬀo, “Cloning
and characterization of murine CD6,” Molecular Immunology,
vol. 32, no. 1, pp. 89–92, 1995.
[28] W. H. Robinson, S. S. Prohaska, J. C. Santoro, H. L.
Robinson, and J. R. Parnes, “Identiﬁcation of a mouse protein
homologous to the human CD6 T cell surface protein and
sequenceofthecorrespondingcDNA,”JournalofImmunology,
vol. 155, no. 10, pp. 4739–4748, 1995.
[29] M.A.A.Castro,M.I.Oliveira,R.J.Nunesetal.,“Extracellular
isoforms of CD6 generated by alternative splicing regulate
targeting of CD6 to the immunological synapse,” Journal of
Immunology, vol. 178, no. 7, pp. 4351–4361, 2007.
[30] L. Cardenas, A. C. Carrera, E. Yague, R. Pulido, F.
Sanchez-Madrid, and M. O. De Landazuri, “Phosphorylation-
dephosphorylation of the CD6 glycoprotein renders two
isoforms of 130 and 105 kilodaltons. Eﬀect of serum and
protein kinase C activators,” Journal of Immunology, vol. 145,
no. 5, pp. 1450–1455, 1990.
[31] N. J. Hassan, S. J. Simmonds, N. G. Clarkson et al.,
“CD6regulatesT-cellresponsesthroughactivation-dependent
recruitment of the positive regulator SLP-76,” Molecular and
Cellular Biology, vol. 26, no. 17, pp. 6727–6738, 2006.
[32] I. Gimferrer, A. Ib´ a˜ nez, M. Farn´ os et al., “The lymphocyte
receptor CD6 interacts with syntenin-1, a scaﬀolding protein
containing PDZ domains,” Journal of Immunology, vol. 175,
no. 3, pp. 1406–1414, 2005.
[33] J. N. Wu and G. A. Koretzky, “The SLP-76 family of adapter
proteins,”SeminarsinImmunology,vol.16,no.6,pp.379–393,
2004.
[34] M. A. A. Castro, R. J. Nunes, M. I. Oliveira et al., “OX52 is the
rat homologue of CD6: evidence for an eﬀector function in
the regulation of CD5 phosphorylation,” Journal of Leukocyte
Biology, vol. 73, no. 1, pp. 183–190, 2003.
[35] S. Wee, G. L. Schieven, J. M. Kirihara, T. T. Tsu, J. A.
Ledbetter, and A. Aruﬀo, “Tyrosine phosphorylation of CD6
by stimulation of CD3: augmentation by the CD4 and CD2
coreceptors,” Journal of Experimental Medicine, vol. 177, no. 1,
pp. 219–223, 1993.
[ 3 6 ]J .K o b a r g ,G .S .W h i t n e y ,D .P a l m e r ,A .A r u ﬀo, and M. A.
Bowen, “Analysis of the tyrosine phosphorylation and calcium
ﬂuxing of human CD6 isoforms with diﬀerent cytoplasmatic
domains,”EuropeanJournalofImmunology,vol.27,no.11,pp.
2971–2980, 1997.
[37] A. Ib´ a˜ nez, M. R. Sarrias, M. Farn´ os et al., “Mitogen-activated
protein kinase pathway activation by the CD6 lymphocyte
surface receptor,” Journal of Immunology, vol. 177, no. 2, pp.
1152–1159, 2006.
[38] R. A. Rasmussen, S. L. Counts, J. F. Daley, and S. F.
Schlossman, “Isolation and characterization of CD6 T cells
from peripheral blood,” Journal of Immunology, vol. 152, no.
2, pp. 527–536, 1994.
[39] D. D. Patel, S. F. Wee, L. P. Whichard et al., “Identiﬁcation and
characterizationofa100-kDligandforCD6onhumanthymic
epithelial cells,” Journal of Experimental Medicine, vol. 181, no.
4, pp. 1563–1568, 1995.
[40] M. A. Bowen, D. D. Patel, X. Li et al., “Cloning, mapping, and
characterization of activated leukocyte-cell adhesion molecule
(ALCAM), a CD6 ligand,” Journal of Experimental Medicine,
vol. 181, no. 6, pp. 2213–2220, 1995.8 Arthritis
[41] M.A.Bowen,J.Bajorath,M.D’Egidioetal.,“Characterization
of mouse ALCAM (CD166): the CD6-binding domain is
conserved in diﬀerent homologs and mediates cross-species
binding,” European Journal of Immunology, vol. 27, no. 6, pp.
1469–1478, 1997.
[42] J. te Riet, A. W. Zimmerman, A. Cambi et al., “Distinct
kinetic and mechanical properties govern ALCAM-mediated
interactions as shown by single-molecule force spectroscopy,”
Journal of Cell Science, vol. 120, no. 22, pp. 3965–3976, 2007.
[43] M. A. Bowen, J. Bajorath, A. W. Siadak et al., “The amino-
terminal immunoglobulin-like domain of activated leukocyte
cell adhesion molecule binds speciﬁcally to the membrane-
proximal scavenger receptor cysteine-rich domain of CD6
with a 1:1 stoichiometry,” Journal of Biological Chemistry, vol.
271, no. 29, pp. 17390–17396, 1996.
[44] M. A. Bowen, A. A. Aruﬀo, and J. Bajorath, “Cell surface
receptors and their ligands: in vitro analysis of CD6-CD166
interactions,” Proteins, vol. 40, no. 3, pp. 420–428, 2000.
[45] F. Cort´ es, F. Deschaseaux, N. Uchida et al., “HCA, an
immunoglobulin-like adhesion molecule present on the ear-
liest human hematopoietic precursor cells, is also expressed by
stromal cells in blood-forming tissues,” Blood, vol. 93, no. 3,
pp. 826–837, 1999.
[46] N. J. Hassan, A. N. Barclay, and M. H. Brown, “Frontline:
optimal T cell activation requires the engagement of CD6 and
CD166,” European Journal of Immunology,v o l .3 4 ,n o .4 ,p p .
930–940, 2004.
[47] R. Cayrol, K. Wosik, J. L. Berard et al., “Activated leukocyte
cell adhesion molecule promotes leukocyte traﬃcking into the
central nervous system,” Nature Immunology, vol. 9, no. 2, pp.
137–145, 2008.
[48] M. C. Levesque, C. S. Heinly, L. P. Whichard, and D. D. Patel,
“Cytokine-regulated expression of activated leukocyte cell
adhesion molecule (CD166) on monocyte-lineage cells and
in rheumatoid arthritis synovium,” Arthritis and Rheumatism,
vol. 41, no. 12, pp. 2221–2229, 1998.
[49] S. M. A. Abidi, M. K. Saifullah, M. D. Zaﬁropulos et
al., “CD166 expression, characterization, and localization in
salivary epithelium: implications for function during siaload-
enitis,” Journal of Clinical Immunology, vol. 26, no. 1, pp. 12–
21, 2006.
[50] S. F. Ofori-Acquah and J. A. King, “Activated leukocyte cell
adhesion molecule: a new paradox in cancer,” Translational
Research, vol. 151, no. 3, pp. 122–128, 2008.
[51] S. F. Wee, W. C. Wang, A. G. Farr et al., “Characterization of a
CD6 ligand(s) expressed on human- and murine-derived cell
lines and murine lymphoid tissues,” Cellular Immunology, vol.
158, no. 2, pp. 353–364, 1994.
[52] Y. S. Joo, N. G. Singer, J. L. Endres et al., “Evidence for the
expression of a second CD6 ligand by synovial ﬁbroblasts,”
Arthritis and Rheumatism, vol. 43, no. 2, pp. 329–335, 2000.
[53] M. K. Saifullah, D. A. Fox, S. Sarkar et al., “Expression and
characterization of a novel CD6 ligand in cells derived from
joint and epithelial tissues,” Journal of Immunology, vol. 173,
no. 10, pp. 6125–6133, 2004.
[54] K. T. Stanley, C. VanDort, C. Motyl, J. Endres, and D. A.
Fox, “Immunocompetent properties of human osteoblasts:
interactions with T lymphocytes,” Journal of Bone and Mineral
Research, vol. 21, no. 1, pp. 29–36, 2006.
[55] M. R. Sarrias, M. Farn´ os, R. Mota et al., “CD6 binds to
pathogen-associated molecular patterns and protects from
LPS-induced septic shock,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 104,
no. 28, pp. 11724–11729, 2007.
[56] J. Vera, R. Fenutr´ ıa, O. Ca˜ nadas et al., “The CD5 ectodomain
interacts with conserved fungal cell wall components and
protects from zymosan-induced septic shock-like syndrome,”
Proceedings of the National Academy of Sciences of the
United States of America, vol. 106, no. 5, pp. 1506–1511,
2009.
[57] M.Ramos-Casals,J.Font,M.Garc´ ıa-Carrascoetal.,“Highcir-
culatinglevelsofsolublescavengerreceptors(sCD5andsCD6)
in patients with primary Sj¨ ogren’s syndrome,” Rheumatology,
vol. 40, no. 9, pp. 1056–1059, 2001.
[58] C. Jamin, G. Magadur, A. Lamour et al., “Cell-free CD5 in
patients with rheumatic diseases,” Immunology Letters, vol. 31,
no. 1, pp. 79–83, 1992.
[59] I. Gimferrer, M. Calvo, M. Mittelbrunn et al., “Relevance of
CD6-mediated interactions in T cell activation and prolifera-
tion,” Journal of Immunology, vol. 173, no. 4, pp. 2262–2270,
2004.
[60] A. W. Zimmerman, B. Joosten, R. Torensma, J. R. Parnes, F. N.
Van Leeuwen, and C. G. Figdor, “Long-term engagement of
CD6 and ALCAM is essential for T-cell proliferation induced
by dendritic cells,” Blood, vol. 107, no. 8, pp. 3212–3220,
2006.
[61] I. Gimferrer, M. Farn´ os, M. Calvo et al., “The accessory
molecules CD5 and CD6 associate on the membrane of
lymphoid T cells,” Journal of Biological Chemistry, vol. 278, no.
10, pp. 8564–8571, 2003.
[ 6 2 ]R .P o s p i s i l ,G .J .S i l v e r m a n ,G .E .M a r t i ,A .A r u ﬀo, M.
A. Bowen, and R. G. Mage, “CD5 is a potential selecting
ligand for B-cell surface immunoglobulin: a possible role in
maintenanceandselectiveexpansionofnormalandmalignant
Bc e l l s , ”Leukemia and Lymphoma, vol. 36, no. 3-4, pp. 353–
365, 2000.
[ 6 3 ]S .G a r a u d ,C .L eD a n t e c ,C .B e r t h o u ,P .M .L y d y a r d ,P .
Youinou, and Y. Renaudineau, “Selection of the alternative
exon 1 from the cd5 gene down-regulates membrane level of
the protein in B lymphocytes,” Journal of Immunology, vol.
181, no. 3, pp. 2010–2018, 2008.
[64] M. A. A. Castro, P. A. Tavares, M. S. Almeida et al., “CD2
physically associates with CD5 in rat T lymphocytes with the
involvement of both extracellular and intracellular domains,”
EuropeanJournalofImmunology,vol.32,no.5,pp.1509–1518,
2002.
[65] M. A. A. Castro, R. J. Nunes, M. I. Oliveira et al., “OX52 is the
rat homologue of CD6: evidence for an eﬀector function in
the regulation of CD5 phosphorylation,” Journal of Leukocyte
Biology, vol. 73, no. 1, pp. 183–190, 2003.
[ 6 6 ]N .G .S i n g e r ,D .A .F o x ,T .M .H a q q ie ta l . ,“ C D 6 :e x p r e s s i o n
during development, apoptosis and selection of human and
mouse thymocytes,” International Immunology, vol. 14, no. 6,
pp. 585–597, 2002.
[67] H. S. Azzam, A. Grinberg, K. Lui, H. Shen, E. W. Shores,
and P. E. Love, “CD5 expression is developmentally regulated
by T cell receptor (TCR) signals and TCR avidity,” Journal of
Experimental Medicine, vol. 188, no. 12, pp. 2301–2311, 1998.
[ 6 8 ]R .A l o n s o ,C .B u o r s ,C .L eD a n t e ce ta l . ,“ A b e r r a n te x p r e s s i o n
of CD6 on B-cell subsets from patients with Sj¨ ogren’s syn-
drome,” Journal of Autoimmunity, vol. 35, no. 4, pp. 336–341,
2010.
[ 6 9 ]C .M .B o t t ,J .B .D o s h i ,C .M o r i m o t o ,P .L .R o m a i n ,a n d
D. A. Fox, “Activation of human T cells through CD6:
functional eﬀects of a novel anti-CD6 monoclonal anti-
body and deﬁnition of four epitopes of the CD6 glycopro-
tein,” International Immunology, vol. 5, no. 7, pp. 783–792,
1993.Arthritis 9
[70] L. M. Osorio, C. Ordonez, C. A. Garcia, M. Jondal, and S. C.
Chow, “Evidence for protein tyrosine kinase involvement in
GD6-induced T cell proliferation,” Cellular Immunology, vol.
166, no. 1, pp. 44–52, 1995.
[71] L. M. Osorio, M. Rottenberg, M. Jondal, and S. C. Chow,
“Simultaneous cross-linking of CD6 and CD28 induces cell
proliferation in resting T cells,” Immunology, vol. 93, no. 3, pp.
358–365, 1998.
[72] R. L. Kirkman, J. L. Araujo, and G. J. Busch, “Treatment
of acute renal allograft rejection with monoclonal anti-T12
antibody,” Transplantation, vol. 36, no. 6, pp. 620–626, 1983.
[73] D. C. Roy, R. Tantravahi, C. Murray et al., “Natural history
of mixed chimerism after bone marrow transplantation with
CD6-depletedallogeneicmarrow:astableequilibrium,”Blood,
vol. 75, no. 1, pp. 296–304, 1990.
[74] N. C. Patel, J. Chinen, H. M. Rosenblatt et al., “Long-term
outcomes of nonconditioned patients with severe combined
immunodeﬁciency transplanted with HLA-identical or hap-
loidentical bone marrow depleted of T cells with anti-CD6
mAb,”JournalofAllergyandClinicalImmunology,vol.122,no.
6, pp. 1185–1193, 2008.
[75] R.J.Soiﬀer,D.Fairclough,M.Robertsonetal.,“CD6-depleted
allogeneic bone marrow transplantation for acute leukemia in
ﬁrst complete remission,” Blood, vol. 89, no. 8, pp. 3039–3047,
1997.